Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 2/20 | 0.53 |
| ▸ | FNTB | P49356 | 2/20 | 0.53 |
| ▸ | SQLE | Q14534 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685900 | 1.00 | KMT2A (0.60) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL16654337 | 1.00 | KMT2A (0.60) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL10986149 | 0.98 | KMT2A (0.64) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL9017121 | 0.98 | KMT2A (0.64) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL794674 | 0.85 | KMT2A (0.58) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL794675 | 0.85 | KMT2A (0.58) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL11787183 | 0.85 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL11787182 | 0.85 | KMT2A (0.44) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL6927178 | 0.82 | KMT2A (0.46) | KMT2AALOX15MEN1CYP3A4MAPT | |
| SCHEMBL6927170 | 0.82 | KMT2A (0.46) | KMT2AALOX15MEN1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1218918-C | Synthesis of geranyl geraniol | UNIV ZHEJIANG (CN) | 2005-09-14 | — | — | CN | claimed |
| CN-1490292-A | Synthesis of geranyl geraniol | 浙江大学 | 2004-04-21 | — | — | CN | claimed |
| JP-1233278-A | — | — | None | — | — | JP | disclosed |
| JP-63250364-A | — | — | None | — | — | JP | disclosed |
| CN-114874072-B | Preparation method of geranylgeraniol | 广西民族师范学院 | 2023-06-23 | — | — | CN | disclosed |
| CN-114874072-A | Preparation method of geranylgeraniol | 广西民族师范学院 | 2022-08-09 | — | — | CN | disclosed |
| US-20220025419-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | GLYCOVAXYN AG (CH) | 2022-01-27 | — | — | US | disclosed |
| EP-3774707-A1 | PROCESS OF VITAMIN K 2 DERIVATIVES PREPARATION | INSTYTUT FARMACEUTYCZNY (PL) | 2021-02-17 | — | — | EP | disclosed |
| US-10800735-B2 | Intermediate compound for manufacturing bixin ethyl ester and method of manufacturing the same | MYONGJI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2020-10-13 | — | — | US | disclosed |
| CN-111592477-A | Novel intermediate compound for preparing norbixin or bixin ethyl ester and preparation method thereof | 明知大学校产学协力团 | 2020-08-28 | — | — | CN | disclosed |
| US-20200262786-A1 | NOVEL INTERMEDIATE COMPOUND FOR MANUFACTURING BIXIN ETHYL ESTER AND METHOD OF MANUFACTURING THE SAME | MYONGI UNIVERSITY INDUSTRY AND ACADEMIA COOPERATION FOUNDATION (KR) | 2020-08-20 | — | — | US | disclosed |
| US-5073659-A | Alkylation, Grignard reagent, zinc chloride catalyst and coppe r compound | EISAI CO., LTD. (JP) | 1991-12-17 | — | — | US | disclosed |
| CN-1049650-A | The terpenic preparation method | EISAI CO LTD (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0414106-A2 | Process for the preparation of terpenes | Eisai Co., Ltd. (JP) | 1991-02-27 | — | — | EP | disclosed |
| JP-H01233278-A | PRODUCTION OF OPTICALLY ACTIVE ALPHA-TOCOTRIENOL | EISAI CO LTD | 1989-09-19 | — | — | JP | disclosed |
| JP-S63250364-A | PRODUCTION OF GERANYLPHENYL SULFONE | KURARAY CO LTD | 1988-10-18 | — | — | JP | disclosed |
| EP-0243849-A2 | Process for the production of polyprenoid type compounds | YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED (IL) | 1987-11-04 | — | — | EP | disclosed |
| EP-0027421-B1 | PROCESS FOR THE PREPARATION OF UNSATURATED SULPHONES, AND SULPHONES OBTAINED | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1982-12-29 | — | — | EP | disclosed |
| US-4343952-A | SULFONATION OF DIENE WITH SULFINATE, PALLADIUM CATALYST | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1982-08-10 | — | — | US | disclosed |
| EP-0027421-A1 | Process for the preparation of unsaturated sulphones, and sulphones obtained | ANVAR Agence Nationale de Valorisation de la Recherche (FR) | 1981-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025419-A1 | N-GLYCOSYLATION OF PEPTIDES AND PROTEINS | PGLS, NGLY1, PTMS | KMT2A 4219/4885ALOX15 4207/4885MEN1 1349/4885 |
| US-20200262786-A1 | NOVEL INTERMEDIATE COMPOUND FOR MANUFACTURING BIXIN ETHYL ESTER AND METHOD OF MANUFACTURING THE SAME | BRIX1, CYP4X1, BROX | KMT2A 3436/4885ALOX15 199/4885MEN1 3013/4885 |
| US-10800735-B2 | Intermediate compound for manufacturing bixin ethyl ester and method of manufacturing the same | BRIX1, BROX, CYP4X1 | KMT2A 3255/4885ALOX15 190/4885MEN1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.